AbbVie Inc. (ABBV)

80.47
0.87 1.10
NYSE : Health Technology
Prev Close 81.34
Open 81.34
Day Low/High 80.37 / 81.75
52 Wk Low/High 75.77 / 121.45
Volume 2.08M
Avg Volume 6.93M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 116.43B
EPS 3.70
P/E Ratio 21.84
Div & Yield 4.28 (5.00%)

Latest News

AbbVie To Present At The Barclays Global Healthcare Conference

AbbVie To Present At The Barclays Global Healthcare Conference

NORTH CHICAGO, Ill., March 1, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Barclays Global Healthcare Conference on Wednesday, March 13, 2019.

AbbVie Receives CHMP Positive Opinion For Risankizumab (SKYRIZI™) For The Treatment Of Moderate To Severe Plaque Psoriasis

AbbVie Receives CHMP Positive Opinion For Risankizumab (SKYRIZI™) For The Treatment Of Moderate To Severe Plaque Psoriasis

- CHMP positive opinion, supported by data from the pivotal Phase 3 program evaluating more than 2,000 patients with moderate to severe plaque psoriasis, will now be reviewed by the European Commission(1-3)

5 Attractive Ways to Invest in Oncology

5 Attractive Ways to Invest in Oncology

Experts offer their top stock ideas in oncology detection and treatment.

AbbVie Becomes #179 Most Shorted S&P 500 Component, Replacing CBRE Group

AbbVie Becomes #179 Most Shorted S&P 500 Component, Replacing CBRE Group

The most recent short interest data has been released for the 02/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

AbbVie To Present At The Cowen Health Care Conference

AbbVie To Present At The Cowen Health Care Conference

NORTH CHICAGO, Ill., Feb.

What's Keeping You Up?: Cramer's 'Mad Money' Recap (Wednesday 2/27/19)

What's Keeping You Up?: Cramer's 'Mad Money' Recap (Wednesday 2/27/19)

Jim Cramer says if you focus on what's going right, you'll sleep better and do a lot better with your money, too.

Waste Management, Weight Watchers, Centene: 'Mad Money' Lightning Round

Waste Management, Weight Watchers, Centene: 'Mad Money' Lightning Round

Jim Cramer weighs in on Waste Management, Weight Watchers, Centene, Aurinia Pharmaceuticals, Activision Blizzard, AbbVie, Cronos Group and more.

AbbVie To Showcase Scientific Innovation And Research Advancements Across Dermatology Portfolio At 2019 AAD Annual Meeting

AbbVie To Showcase Scientific Innovation And Research Advancements Across Dermatology Portfolio At 2019 AAD Annual Meeting

- Nineteen abstracts underscore AbbVie's continued pursuit of research on behalf of patients living with chronic dermatologic conditions

Voyager Shares Take Off on Parkinson's Disease Development Deal

Voyager Shares Take Off on Parkinson's Disease Development Deal

AbbVie to provide multi-million-dollar financing to Voyager to develop and commercialize potential Parkinson's treatment.

AbbVie And Voyager Therapeutics Announce Collaboration To Develop Vectorized Antibodies To Treat Parkinson's Disease And Other Synucleinopathies

AbbVie And Voyager Therapeutics Announce Collaboration To Develop Vectorized Antibodies To Treat Parkinson's Disease And Other Synucleinopathies

- Deal expands collaborative efforts on vectorized antibodies to target pathological species of alpha-synuclein

AbbVie Declares Quarterly Dividend

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., Feb.

AbbVie Announces New Drug Application Accepted For Priority Review By U.S. FDA For Upadacitinib For Treatment Of Moderate To Severe Rheumatoid Arthritis

AbbVie Announces New Drug Application Accepted For Priority Review By U.S. FDA For Upadacitinib For Treatment Of Moderate To Severe Rheumatoid Arthritis

- Upadacitinib, an investigational once-daily oral JAK1-selective inhibitor, is being studied for the treatment of adult patients with moderate to severe rheumatoid arthritis[1-8]

AbbVie And Teneobio Announce A Strategic Transaction To Develop A New Treatment For Multiple Myeloma

AbbVie And Teneobio Announce A Strategic Transaction To Develop A New Treatment For Multiple Myeloma

NORTH CHICAGO, Ill. and MENLO PARK, Calif.

Johnson Fistel, LLP Announces Investigations Of AbbVie Inc., Macquarie Infrastructure Corporation, OPKO Health, Inc. And Uxin Limited; Investors Encouraged To Contact Firm

Johnson Fistel, LLP Announces Investigations Of AbbVie Inc., Macquarie Infrastructure Corporation, OPKO Health, Inc. And Uxin Limited; Investors Encouraged To Contact Firm

SAN DIEGO, Feb. 5, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against the following companies: AbbVie Inc.

Dividend Aristocrats Welcome a New Class of Nobility

Of the 57 index constituents, four Aristocrats have yields above 4.0%.

Watch Out for the Wave: Cramer's 'Mad Money' Recap (Tuesday 1/29/19)

Watch Out for the Wave: Cramer's 'Mad Money' Recap (Tuesday 1/29/19)

Jim Cramer says that if expectations are too high, even a great quarter cannot save you from the wave of selling.

Carvana, Bank OZK, Idexx Labs: 'Mad Money' Lightning Round

Carvana, Bank OZK, Idexx Labs: 'Mad Money' Lightning Round

Jim Cramer takes a look at Carvana, Bank OZK, Idexx Labs, Patterson-UTI Energy, 3D Systems, AbbVie and more.

Dow Closes Higher to End Week With Modest Gains

Dow Closes Higher to End Week With Modest Gains

Stocks rose by Friday's close, getting a boost from a number of strong corporate earnings reports even as investors continue to worry about a lack of progress in U.S.-China trade talks.

AbbVie Falls After Missing Top- and Bottom-Line Estimates

AbbVie Falls After Missing Top- and Bottom-Line Estimates

The pharmaceutical company reports fourth-quarter results below analysts' consensus forecasts.

Why Risk-On Is In Vogue, Updating Zuora: Market Recon

Why Risk-On Is In Vogue, Updating Zuora: Market Recon

China's central bank announced a bill swap mechanism late Thursday aimed at slowing down the nation's economic slowdown.

AbbVie Reports Full-Year And Fourth-Quarter 2018 Financial Results

AbbVie Reports Full-Year And Fourth-Quarter 2018 Financial Results

- Reports Full-Year Diluted EPS of $3.66 on a GAAP Basis; Adjusted Diluted EPS of $7.91 Reflects Growth of 41.3 Percent

AbbVie Provides Update On Phase 3 Study Of Ibrutinib (IMBRUVICA®) In Metastatic Pancreatic Cancer

AbbVie Provides Update On Phase 3 Study Of Ibrutinib (IMBRUVICA®) In Metastatic Pancreatic Cancer

-- The RESOLVE (PCYC-1137) trial evaluated ibrutinib in combination with chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Flexible, Patient Fed: Cramer's 'Mad Money' Recap

Flexible, Patient Fed: Cramer's 'Mad Money' Recap

Jim Cramer talks about the Fed, and outlines your game plan.

Qualcomm, Momo, Ciena: 'Mad Money' Lightning Round

Qualcomm, Momo, Ciena: 'Mad Money' Lightning Round

Jim Cramer weighs in on Qualcomm, Momo, Ciena, AbbVie, LM Ericsson and more.

Keep an Eye on Earnings: Cramer's 'Mad Money' Recap (Thursday 1/3/19)

Keep an Eye on Earnings: Cramer's 'Mad Money' Recap (Thursday 1/3/19)

Jim Cramer says a trade deal could help, but what matters after today is earnings -- and how bad the shortfalls will be.

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

TheStreet Quant Rating: B- (Buy)